Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy

Vascular endothelial growth factor (VEGF) has been shown to be an endothelial cell-specific mitogen and an angiogenic inducer in a variety of in vitro and in vivo models. Furthermore, it has been demonstrated to increase retinal vessel permeability by increasing the phosphorylation of tight junction...

Descripción completa

Detalles Bibliográficos
Autor principal: Fernando Arevalo, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Hypothesis, Discovery & Innovation Ophthalmology 2013
Materias:
Brief Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939761/
https://www.ncbi.nlm.nih.gov/pubmed/24600636
_version_ 1782305739456380928
author Fernando Arevalo, J.
author_facet Fernando Arevalo, J.
author_sort Fernando Arevalo, J.
collection PubMed
description Vascular endothelial growth factor (VEGF) has been shown to be an endothelial cell-specific mitogen and an angiogenic inducer in a variety of in vitro and in vivo models. Furthermore, it has been demonstrated to increase retinal vessel permeability by increasing the phosphorylation of tight junction proteins. Recent work has found elevated levels of VEGF in ocular fluids of patients with proliferative diabetic retinopathy (PDR). Thus, it makes sense to consider anti-VEGF treatments in the management of PDR. The purpose of the current research is to determine if intravitreal bevacizumab as anti-VEGF is helpful in the management of complications of PDR.
format Online
Article
Text
id pubmed-3939761
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medical Hypothesis, Discovery & Innovation Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-39397612014-03-05 Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy Fernando Arevalo, J. Med Hypothesis Discov Innov Ophthalmol Brief Review Vascular endothelial growth factor (VEGF) has been shown to be an endothelial cell-specific mitogen and an angiogenic inducer in a variety of in vitro and in vivo models. Furthermore, it has been demonstrated to increase retinal vessel permeability by increasing the phosphorylation of tight junction proteins. Recent work has found elevated levels of VEGF in ocular fluids of patients with proliferative diabetic retinopathy (PDR). Thus, it makes sense to consider anti-VEGF treatments in the management of PDR. The purpose of the current research is to determine if intravitreal bevacizumab as anti-VEGF is helpful in the management of complications of PDR. Medical Hypothesis, Discovery & Innovation Ophthalmology 2013 /pmc/articles/PMC3939761/ /pubmed/24600636 Text en © 2013, Medical Hypothesis, Discovery & Innovation (MEHDI) Ophthalmology Journal This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Review
Fernando Arevalo, J.
Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
title Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
title_full Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
title_fullStr Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
title_full_unstemmed Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
title_short Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
title_sort intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy
topic Brief Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939761/
https://www.ncbi.nlm.nih.gov/pubmed/24600636
work_keys_str_mv AT fernandoarevaloj intravitrealbevacizumabasantivascularendothelialgrowthfactorinthemanagementofcomplicationsofproliferativediabeticretinopathy

Ejemplares similares